Gilead Sciences · 1 day ago
Scientist, Analytical Operations
Oceanside, CA
Full-time
Onsite
Mid, Senior Level
$133K/yr - $172K/yr
4+ years expGilead Sciences is dedicated to creating a healthier world for all people, focusing on developing therapies for diseases such as HIV and cancer. The Scientist, Analytical Operations will be responsible for developing and optimizing workflows for N-glycan analysis and driving structural elucidation of N-glycans, while also supporting assessments and authoring technical reports.
BiopharmaBiotechnologyHealth CareManufacturingPharmaceutical
Responsibilities
Develop and optimize N-glycan analysis workflows (HILIC-FLD, LC-MS, CE-LIF etc.), including sialic acid, NGNA, α‑Gal characterization and quantitation analysis
Drive advanced structural elucidation of N-glycans using LC‑MS/MS, exoglycosidase sequencing, linkage analysis, monosaccharide analysis, and orthogonal structural tools
Perform intact and subunit mass spectrometry, as well as glycopeptide mapping, to define glycan occupancy, site-specific heterogeneity, and structural impacts on the protein backbone
Integrate glycan structural information with functional outcomes such as Fc receptor binding, Fc silencing/attenuation, CH2 stability, higher-order structure changes, aggregation, and immunogenicity risk
Support glycosylation pCQA/CQA assessments, providing mechanism interpretation, structure-function justifications, and cross-program scientific guidance
Support glycan-driven structural differences assessment in comparability studies
Author technical reports, glycan characterization summaries, method development documentation, and regulatory submission content
Continuously evaluate and implement emerging innovations in glycomics, glycoproteomics, and computational structure–function modeling
Qualification
Required
BS with +6 years of relevant experience in Analytical Chemistry, Glycobiology, Biochemistry, Biophysics, or related field OR
MS with +4 years of relevant experience in Analytical Chemistry, Glycobiology, Biochemistry, Biophysics, or related field OR
PhD with 0 years of relevant experience in Analytical Chemistry, Glycobiology, Biochemistry, Biophysics, or related field
Hands-on experience with LC‑MS or MS/MS for glycan or glycoprotein structural characterization
Strong analytical reasoning and the ability to interpret complex structure–function relationships
Excellent communication skills and ability to work effectively in a cross-functional, matrixed environment
Preferred
Deep expertise in glycan structural elucidation (MS/MS fragmentation, linkage analysis, exoglycosidase workflows)
Experience linking glycan features to biological activity: FcγR binding, effector function modulation, CH2/HOS stability, aggregation, or PK
Proficiency with intact/subunit MS, peptide mapping, CE-SDS, SEC-MALS, cIEF and UPLC/HPLC techniques
Knowledge of therapeutic antibody glycosylation, Fc engineering strategies, and effector-function silencing frameworks
Familiarity with ICH Q5E/Q6B and analytical method qualification for glycan assays
Experience with MS analysis tools (Protein Metrics, Peaks etc.) and analytics platforms (JMP etc.)
Benefits
Discretionary annual bonus
Discretionary stock-based long-term incentives (eligibility may vary based on role)
Paid time off
Company-sponsored medical, dental, vision, and life insurance plans
Company
Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for critical diseases.
10001+ employees
H1B Sponsorship
Gilead Sciences has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (269)
2024 (241)
2023 (222)
2022 (208)
2021 (235)
2020 (187)
Funding
Current Stage
Public CompanyTotal Funding
$4.41BKey Investors
Abingworth
2024-11-13Post Ipo Debt· $3.5M
2024-02-29Post Ipo Equity· $210M
2023-09-07Post Ipo Debt· $2B
Leadership Team
Keeley Wettan
Senior Vice President, Legal
Patrick Loerch
Senior Vice President, Clinical Data Science
Recent News
2026-01-09
2026-01-08
2026-01-07
Company data provided by crunchbase